ABSI Stock Surges After Positive Hair Loss Drug Data, $100M Lilly Backing
Absci Corporation announced that its drug ABS-201 was well-tolerated and showed long-lasting presence in the body in a clinical trial. The stock surged over 50% in pre-market trading.
Key Numbers
Absci Corporation (NASDAQ: ABSI) reported positive clinical trial data for its investigational hair loss drug ABS-201, sending its stock to a record single-day gain. The trial showed the drug was well-tolerated and demonstrated prolonged drug exposure.
The Product
ABS-201 is an experimental biologic targeting a novel pathway for hair loss. Early data indicate good tolerability and a long pharmacokinetic profile, which could allow less frequent dosing compared to existing treatments.
Pricing and Availability
Absci has not disclosed pricing for ABS-201, as it remains in early clinical development. Regulatory approval and market launch are likely years away.
Competition
ABS-201 competes with established treatments like minoxidil and finasteride, as well as emerging therapies. Absci bets on its unique mechanism and extended duration to differentiate itself.
Potential Impact on the Company
The $100 million investment from Eli Lilly (LLY) supports ABS-201's development, boosting Absci's credibility. If successful, the drug could tap into a large market for hair loss treatments.
Frequently Asked Questions
Found this useful? Share it